PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.

3,4-Dihydroxybenzylamine hydrobromide inhibits DNA polymerase activity in melanoma cells and displays growth inhibitory activity in melanoma cell lines with varying degrees of tyrosinase activity.

Ontuxizumab (MORAb-004) is a potent IgG1/κ monoclonal antibody targeting endomelanic acid with anti-tumor effects.